Leap Therapeutics Inc (STU:5MC)

€ 2.62 -0.1 (-3.68%) Market Cap: 101.82 Mil Enterprise Value: 42.34 Mil PE Ratio: 0 PB Ratio: 2.27 GF Score: 35/100

Leap Therapeutics Inc ASCO GI 2024 DeFianCe Study Webcast Transcript
Jan 23, 2024
Leap Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 10, 2024
Leap Therapeutics Inc at Robert W Baird Global Healthcare Conference Transcript
Sep 13, 2023
Leap Therapeutics Inc at HC Wainwright Investment Conference - New York Transcript
Sep 11, 2023
Leap Therapeutics Inc Annual Shareholders Meeting Transcript
Jun 16, 2023
Leap Therapeutics Inc Acquires Flame Biosciences Transcript
Jan 17, 2023
Leap Therapeutics Inc at Piper Sandler Healthcare Conference Transcript
Nov 29, 2022
Leap Therapeutics Inc - R&D Day Transcript
Jul 12, 2022
Leap Therapeutics Inc ASCO GI 2022 DisTinGuish Study Conference Call Transcript
Jan 21, 2022
Leap Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 13, 2022
Leap Therapeutics Inc ESMO 2021 DisTinGuish Study Conference Call Transcript
Sep 17, 2021
Leap Therapeutics Inc at Ladenburg Thalmann Virtual Healthcare Conference Transcript
Jul 14, 2021
Leap Therapeutics Inc at Raymond James Human Health Innovation Conference (Virtual) Transcript
Jun 21, 2021
Leap Therapeutics Inc DKN-01 Clinical Data Conference Call Transcript
Mar 22, 2021
Leap Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 14, 2021
Leap Therapeutics Inc Annual Shareholders Meeting Transcript
Jun 16, 2020
Leap Therapeutics, Inc. - Special Call Transcript
Apr 23, 2020
Leap Therapeutics, Inc. - Special Call Transcript
Aug 06, 2019

Leap Therapeutics Inc at Piper Sandler Healthcare Conference Transcript

Nov 29, 2022 / 09:00PM GMT

Release Date Price: €5.2 (-4.16%)

Transcript

Joe Catanzaro

Piper Sandler Companies - Analyst

Well, great. Thanks, everybody, for joining us here in person and those here on the webcast for Piper Sandler's Annual Healthcare Conference. I'm Joe Catanzaro from Piper's biotech team. It's my pleasure to welcome Leap Therapeutics and their CEO, Doug Onsi.

Doug, thanks so much for making the time and joining us here. Lots of things I want to cover and discuss here. But maybe first, I could just hand it over to you and you could level set the discussion and give a little update on what Leap's been up to and what we have to look forward to.

Doug Onsi

Leap Therapeutics, Inc. - President & CEO

Well, great. Thank you very much, Joe. I appreciate the opportunity to speak here at Piper and thank everyone for listening in on the webcast and joining us here in person.

Leap is an oncology-focused drug development company, and we're focused on developing our monoclonal antibody, DKN-01. And DKN-01 targets a protein called DKK1, and DKK1 is produced by cancer cells. And when it's produced and

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.